诺华以30亿美元收购实验性乳腺癌药物

格隆汇
Yesterday

诺华宣布,已与Synnovation Therapeutics达成协议,收购泛突变选择性PI3Kα抑制剂SNV4818,旨在探索治疗HR+/HER2-乳腺癌患者以及潜在其他实体瘤适应症的下一代治疗方案。SNV4818是一种口服药物,目前正在针对乳腺癌及其他晚期实体瘤开展I/II期临床研究。根据协议条款,诺华将向Synnovation Therapeutics支付20亿美元的预付款以及最高10亿美元的里程碑付款,以收购Synnovation的全资子公司Pikavation Therapeutics。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10